Compare MIRM & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | LBRDK |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.4B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | LBRDK |
|---|---|---|
| Price | $89.49 | $53.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $112.00 | N/A |
| AVG Volume (30 Days) | 601.2K | ★ 1.1M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $24.61 | N/A |
| Revenue Next Year | $21.75 | $109.28 |
| P/E Ratio | ★ N/A | $10.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.88 | $42.10 |
| 52 Week High | $109.28 | $104.00 |
| Indicator | MIRM | LBRDK |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 53.82 |
| Support Level | $72.17 | $52.00 |
| Resistance Level | $107.51 | $57.84 |
| Average True Range (ATR) | 3.75 | 1.65 |
| MACD | -2.53 | -0.33 |
| Stochastic Oscillator | 12.45 | 28.08 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.